Dual-Mechanism Drop Wins FDA Approval - Takeaways - MDSpire

Dual-Mechanism Drop Wins FDA Approval

FDA approves Tenpoint Therapeutics’ YUVEZZI eye drop for presbyopia

  • February 2, 2026

  • 2 min

Share

  • 1

    YUVEZZI™ is the first FDA-approved dual-agent eye drop for treating presbyopia in adults.

  • 2

    The formulation combines carbachol and brimonidine tartrate to improve near visual acuity while preserving distance vision.

  • 3

    FDA approval was based on two Phase 3 trials, BRIO I and BRIO II, involving over 800 patients.

  • 4

    YUVEZZI demonstrated significant improvements in near vision without serious adverse events during extensive safety studies.

  • 5

    The product is expected to be commercially available in the US by the second quarter of 2026.

Original Source(s)

Dual-Mechanism Drop Wins FDA Approval

  • February 2, 2026

Related Content

Evaluating Postoperative Visual Performance and Reading Abilities of a Non-Diffractive EDOF IOL Compared to a Monofocal IOL: A Randomized Controlled Study on Eye Movements

Lenz Therapeutics Announces FDA Approval of Vizz for the Treatment of Presbyopia

Near vision improvements were demonstrated within 30 minutes and lasted up to 10 hours in clinical trials.

  • July 8, 2025

  • 2 min
Navigating Presbyopia Conversations With Confidence

Understanding the concept of ocular maturity helps staff frame presbyopia as a natural, manageable process with modern solutions.